🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Implantica CE Reflux clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our Germany, Switzerland, Spain, Italy, Norway and Austria registers with Implantica CE Reflux as lead sponsor. Synced 26 Sep 2026
3Current trials
1Recruiting now
0Drugs in these trials
6Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Implantica CE Reflux is the lead sponsor of 3 current clinical trials in our Germany, Switzerland, Spain, Italy, Norway and Austria registers. 1 is recruiting patients now. The most common phase is Not applicable. The most-studied condition is Gastroesophageal Reflux Disease.

ClinicalTrials.gov trials by status

  • Recruiting133%
  • Not yet open267%

Trials by phase

  • Not applicable267%
  • Observational133%
01

Clinical trials sponsored by Implantica CE Reflux

3 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Post-Market Registry for the Evaluation of RefluxStop in GERD Treatment
NCT05870163 · ClinicalTrials.gov ↗ · Gastroesophageal Reflux Disease (GERD)
Observational Recruiting 2023-02 Germany, Italy, Switzerland, Norway
A Post-market Registry to Assess Safety and Performance of RefluxStop™ in the Treatment of GERD in General Hospital Practice
NCT07004439 · ClinicalTrials.gov ↗ · Gastroesophageal Reflux Disease
Not applicable Not yet open 2025-09 Germany, Spain
A Blinded Randomized Clinical Study of RefluxStop™ Compared With Nissen Fundoplication in the Treatment of GERD
NCT07004400 · ClinicalTrials.gov ↗ · GERD (Gastroesophageal Reflux Disease)
Not applicable Not yet open 2025-08 Germany, Switzerland, Austria

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Conditions in Implantica CE Reflux trials

3 conditions
Gastroesophageal Reflux Disease1Gastroesophageal Reflux Disease (GERD)1GERD (Gastroesophageal Reflux Disease)1
03

By trial register

RegisterTrialsRecruiting
Clinical trials in Germany31
Clinical trials in Switzerland21
Clinical trials in Spain10
Clinical trials in Italy11
Clinical trials in Norway11
Clinical trials in Austria10

A trial with sites in more than one country appears in each of those registers.

04

Other sponsors in Gastroesophageal Reflux Disease

SponsorTrials
Carnot Laboratories1

Sponsors with the most current trials registered for this condition.

05

Questions about Implantica CE Reflux trials

How many clinical trials does Implantica CE Reflux sponsor?

Implantica CE Reflux is the lead sponsor of 3 current trials on ClinicalTrials.gov in our Germany, Switzerland, Spain, Italy, Norway and Austria registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Implantica CE Reflux trials recruiting?

Yes. 1 of its 3 ClinicalTrials.gov trials is recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.